Drug-induced parkinsonism;Les syndromes parkinsoniens médicamenteux

Therapie

Volumn 59, Issue 1, 2004, Pages 105-112

  Ngugen, Nhan ^a   Pradel, Vincent ^a   Micallef, Joëlle ^a   Montastruc, Jean Louis ^b   Blin, Olivier ^a,c  

^a CNRS   (France)

^b UNIVERSITÉ DE TOULOUSE   (France)

^c TIMONE HOSPITAL   (France)

Author keywords

Drug induced; Parkinsonism; Pharmacovigilance

Indexed keywords

AMISULPRIDE; ANTIDEPRESSANT AGENT; BENZAMIDE; BUTYROPHENONE DERIVATIVE; CALCIUM CHANNEL BLOCKING AGENT; CHLORPROMAZINE; CLOZAPINE; CYAMEMAZINE; DIAZEPINE DERIVATIVE; DOPAMINE 2 RECEPTOR; DROPERIDOL; FLUPENTIXOL; HALOPERIDOL; LEVOMEPROMAZINE; LITHIUM; NEUROLEPTIC AGENT; OLANZAPINE; OXAZEPINE DERIVATIVE; PHENOTHIAZINE; PIPAMPERONE; RESERPINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; SULPIRIDE; SULTOPRIDE; TENSIONORME; THIOXANTHENE; TIAPRIDE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VALPROIC ACID; ZUCLOPENTHIXOL DECANOATE;

BODY POSTURE; CONFERENCE PAPER; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG INDUCED DISEASE; DRUG WITHDRAWAL; EXTRAPYRAMIDAL SYMPTOM; HUMAN; MUSCLE RIGIDITY; PARKINSONISM; PRIORITY JOURNAL; RISK; SIDE EFFECT; STRIATE CORTEX; SYMPTOM; TREMOR;

EID: 2942695746     PISSN: 00405957     EISSN: None     Source Type: Journal    
DOI: 10.2515/therapie:2004021     Document Type: Conference Paper

References (56)

1. Hugues AJ, Daniel SE, Kilford L, et al. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathologic study of 100 cases. J Neurol Neurosurg Psychiatry 1992; 55: 181-4
2. Forno LS. Neuropathology of Parkinson's disease. J Neuropathol Exp Neurol 1996; 55: 259-72
3. Langston JW, Ballard PA. Parkinson's disease in a chemist working with 1-methyl-4-phenyl-1,2,3,6,-tetrahydropyridine (MPTP) [letter]. N Engl J Med 1983; 309 (5): 310
4. Rascol A. La maladie de Parkinson. Paris: Acanthe, 1998; 1: 246
5. Ricaurte GA, Yuan J, Hatzidimitriou G, et al. Severe dopaminergic neurotoxicity in primates after a common recreational dose regimen of MDMA ('ecstasy'). Science 2002; 297: 2260-3
6. Ricaurte GA, Yuan J, Hatzidimitriou G, et al. Retraction. Science 2003; 301: 1479
7. Guilarte TR. Is methamphetamine abuse a risk factor in parkinsonism? Neurotoxicology 2001; 22 (6): 725-31
8. Montastruc JL, Llau ME, Rascol O, et al. Drug-induced parkinsonism: a review. Fundam Clin Pharmacol 1994; 8: 293-306
9. Montastruc JL, Llau-Bousquet ME, Senard JM, et al. Mouvements anormaux d'origine médicamenteuse. Rev Prat 1997; 47: 1109-16
10. Tazaroute M, Bordet R, Catteau J, et al. Adverse drug reaction in hospitalized patients with psychiatric disorders: detection and cost analysis [poster]. 19ème journées de pharmacovigilance; 1998 mars 23-25; Nancy
11. De Rijk MC, Tzourio C, Breteler MMB, et al. Prevalence of parkinsonism and Parkinson's disease in Europe: the Europarkinson Collaborative Study. J Neurol Neurosurg Psychiatry 1997; 62: 10-5
12. Llau ME, Nguyen L, Senard JM, et al. Syndromes parkinsoniens d'origine médicamenteuse: expérience d'un centre régional de pharmacovigilance sur dix ans. Rev Neurol 1994; 150: 757-62
13. Jimenez-Jimenez FJ, Orti-Pareja M, Ayuso-Peralta L, et al. Drug-induced parkinsonism in a movement disorders unit: a four-year survey. Parkinsonism Relat Disord 1996; 2: 145-9
14. Micheli F, Pardal MF, Gatto M, et al. Flunarizine and cinnarizine-induced extrapyramidal reactions. Neurology 1987; 7: 881-4
15. Micheli FE, Fernandez Pardal M, Giannaula R, et al. Movement disorder and depression due to flunarizine and cinnarizine. Mov Disord 1989; 4: 139-46
16. Damier P. Mouvements anormaux. Pour la pratique. Rev Prat 1997; 47: 1117-20
17. Thobois S, Guillouet S, Broussolle E. Contributions of PET and SPECT to the understanding of the physiopathology of Parkinson's disease. Neurophysiol Clin 2001; 31: 321-40
18. Jimenez-Jimenez FJ, Garcia-Ruiz PJ, Molina JA. Drug-induced movement disorders. Drug Saf 1997; 16 (3): 180-204
19. Duchêne-Marullaz P. Histoire de la neuropharmacologie. In: Dehen H, Dordain G, editors. Neuropharmacologie clinique, le médicament en neurologie, Paris: Doin, 1989: 1-11
20. Delay J, Denicker P. In: Garattini S, Ghetti V, editors. Psychotropic drugs. Amsterdam: Elsevier, 1957: 485-501
21. Westerink BHC. Can antipsychotic drugs be classified by their effects on a particular group of dopamine neurons in the brain? Eur J Pharmacol 2002; 455: 1-18
22. Farde L, Nordstrom AL, Wiesel AL, et al. Positron emission tomographic analysis of central D2 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. J Clin Psychiatry 1992; 9: 538-44
23. Farde L, Nordstrom AL, Nyberg S, et al. D1-, D2-, and 5-HT2-receptor occupancy in clozapine-treated patients. J Clin Psychiatry 1994; 55 Suppl. B: 67-B69
24. Kapur S, Zipursky RB, Jones C, et al. The D2 receptor occupancy profile of loxapine determined using PET. Neuropsychopharmacology 1996; 15 (6): 562-6
25. Heck AH, Haffmans PMJ, de Groot IW, et al. Risperidone versus haloperidol in psychotic patients with disturbing neuroleptic-induced extrapyramidal symptoms: a double-blind, multi-center trial. Schizophr Res 2000; 46: 97-105
26. Nyberg S, Farde L, Halldin C. A PET study of 5-HT2 and D2 dopamine receptor occupancy induced by olanzapine in healthy subjects. Neuropsychopharmacology 1997; 16: 1-7
27. Nyberg S, Nordstrom AL, Halldin C, et al. Positron emission tomography studies on D2 dopamine receptor occupancy and plasma antipsychotic drug levels in man. Int Clin Psychopharmacol 1995; 10 Suppl. 3: 81-5
28. Remington G, Kapur S. D2 and 5-HT2 receptor effects of antipsychotics: bridging basic and clinical findings using PET. J Clin Psychiatry 1999; 60 Suppl. 10: 15-9
29. Breier A, Malhotra A, Su T, et al. Clozapine and risperidone in chronic schizophrenia: effects on symptoms, parkinsonian side effects and neuroendocrine response. Am J Psychiatry 1999; 156: 294-8
30. Miller CH, Mohr F, Umbrich D, et al. The prevalence of acute extrapyramidal symptoms in patients treated with clozapine, risperidone and conventional antipsychotics. J Clin Psychiatry 1998; 59: 69-75
31. Bronson B, Lindenmayer JP. Adverse effects of high-dose olanzapine in treatment-refractory schizophrenia. J Clin Psychopharmacol 2000; 20: 382-4
32. Chambers RA, Caracansi A, Weiss G. Olanzapine overdose cause of acute extrapyramidal symptoms. Am J Psychiatry 1998; 155: 1630-1
33. Rudolf J, Ghaemi M, Schmülling S. Deterioration of parkinsonian symptoms following treatment of dopaminergic hallucinosis with olanzapine. Eur Psychiatry 1999; 14: 356-7
34. Abadie P, Dollfus S. Neuroleptiques: principes et règles d'utilisation. Rev Prat 1999; 49: 2135-44
35. Teive HAG, Sa DS. Worsening of Parkinsonism after the use of veralipride for treatment of menopause: case report. Arq Neuropsiquiatr 2001; 59 (1): 123-4
36. Jean-Pastor MJ, Rodor F, Nguyen N, et al. Evaluation de l'impact d'une lettre d'information sur le métoclopramide. Thérapie 1999; 54: 63-4
37. Negrotti A, Calzetti S. A long-term follow-up study of cinnarizine- and flunarizine-induced parkinsonism. Mov Disord 1997; 12 (1): 107-10
38. Malaterre HR, Lauribe P, Paganelli F, et al. Syndrome parkinsonien, effet indésirable possible des inhibiteurs calciques. Arch Mal Cœur Vaiss 1992; 85: 1335-7
39. Sempere AP, Duarte J, Cabezas C, et al. Parkinsonism induced by amlodipine. Mov Disord 1995; 10: 115-6
40. Remblier C, Kassir A, Richard D, et al. Syndrome parkinsonien sous diltiazem. Thérapie 2001; 56: 57-9
41. Teive HAG. Parkinsonian syndrome induced by amlodipine: case report. Mov Disord 2002; 17: 833-5
42. Montastruc JL, Fabre N, Blin O. Does fluoxetine aggravate Parkinson's disease?: a pilot prospective study. Mov Disord 1995; 10: 355-7
43. Lambert MT, Trutia C, Petty F. Extrapyramidal adverse effects associated with sertraline. Prog Neuropsychopharmacol Biol Psychiatry 1998; 22: 741-8
44. Arya DK, Szabadi E. Dyskinesia associated with fluvoxamine. J Clin Psychopharmacol 1993; 13: 365-6
45. Arya DK. Extrapyramidal symptoms with selective serotonin reuptake inhibitors. Br J Psychiatry 1994; 165: 728-33
46. Lipinski JF, Mallya G, Zimmerman P, et al. Fluoxetine-induced akathisia: clinical and theorical implications. J Clin Psychiatry 1989; 50: 339-42
47. Caley CF. Extrapyramidal reactions and the selective serotonin-reuptake inhibitors. Ann Pharmacother 1997; 31: 1481-9
48. Mathen D, Marsden CD, Bathia KP. SSRI-induced reversal of levodopa benefit in two patients with dopa-responsive dystonia. Mov Disord 1999; 14: 874-6
49. Vandel P, Bonin B, Leveque E, et al. Tricyclic antidepressant-induced extrapyramidal side effects. Eur Neuropsychopharmacol 1997; 7: 207-12
50. Gammon GD, Hansen C. A case of akinesia induced by amoxapine. Am J Psychiatry 1984; 141: 283-4
51. Gony M, Lapeyre-Mestre M, Montastruc JL, et al. Risk of serious extrapyramidal symptoms in patients with Parkinson's disease receiving antidepressant drugs: a pharmacoepidemiologic study comparing serotonin reuptake inhibitors and other antidepressant drugs. Clin Neuropharmacol 2003; 26 (3): 142-5
52. Kelwala S, Pomara N, Stanley M, et al. Lithium-induced accentuation of extrapyramidal symptoms in individuals with Alzheimer's disease. J Clin Psychiatry 1984; 45: 342-4
53. Johnels B, Wallin L, Walinder J. Extrapyramidal side effects of lithium treatment [letter]. BMJ 1976 (6036); 2: 642
54. Armon C, Shin C, Miller P, et al. Reversible parkinsonism and cognitive impairment with chronic valproate use. Neurology 1996; 47: 626-35
55. Masmoudi K, Gras-Champel V, Bonnet I, et al. Démence et troubles extrapyramidaux sous acide valproïque au long cours. Thérapie 2000; 55: 629-34
56. Iijima M. Valproate-induced parkinsonism in a demented elderly patient. J Clin Psychiatry 2002; 63 (1): 75